Evan Vassos (@evanvassos) header
Evan Vassos (@evanvassos) profile picture

🎓 MBA | BCom 💼 Founder & Director | Dolphin Corporate Investments 📢 Opinions are my own. Not investment advice.

Australia
Joined July 2012
Dolphin Corporate Investments has moved offices. We are now located at 130 Little Collins Street, Melbourne. I look forward to welcoming clients and ASX companies to our new office.
5
22
4,047
$60B At-The-Market program for $META
🚨 BREAKING: Meta launches ~$35B stock sale to fund its AI buildout $22.5B of common stock plus $12.5B of mandatory convertible preferred, and a planned ~$60B at-the-market program once Class C shares trade. Nvidia, AMD and Broadcom have indicated interest in buying up to $5B, per Meta's statement. $META $NVDA
1
180
😳
Turns out the future does have flying cars
120
🇯🇵😮‍💨
1
100
Wharfie Time 😬
What the hell just happened?! #AFLGF
1
2
1,022
We knew he was a champion
A Brownlow Medallist at 23 years old.
1
258
Never in doubt.
The prodigy becomes an icon🥇 Nick Daicos becomes our club’s 10th Brownlow Medallist!
1
248
Sinclair Gold (ASX: SGC) Mt Henry Gold Project resource has doubled to 1.8Moz at 1.2g/t gold. +0.9Moz in six months since acquiring the project in February 2026. Over 70% is in the higher-confidence Measured & Indicated category and approx 90% sits within 200m of surface, pointing to shallow, open-pit potential. Growth is ongoing: mineralisation remains open at depth and along strike, 25 step-out holes have assays pending, and five rigs are now drilling. Targeting another resource update before the end of FY27.
320
Sinclair Gold (ASX: SGC) Mt Henry Gold Project resource has doubled to 1.8Moz at 1.2g/t gold. +0.9Moz in six months since acquiring the project in February 2026. Over 70% is in the higher-confidence Measured & Indicated category and approx 90% sits within 200m of surface, pointing to shallow, open-pit potential. Growth is ongoing: mineralisation remains open at depth and along strike, 25 step-out holes have assays pending, and five rigs are now drilling. Targeting another resource update before the end of FY27.
1
457
All for this.
Collingwood will unveil a new pre-game ritual against the Cats on Thursday night. They’re asking fans to help choose an anthem for future matches akin to Port Adelaide’s “Never Tear Us Apart”. READ MORE 👉 bit.ly/4xfZK37
223
Announcement by Amplia Therapeutics released on the OTCQB Venture Market $ATX $ATX.AX Worthy of a read otcmarkets.com/stock/INNMF/n…
"In the future, Narmafotinib may be eligible for Accelerated Approval and Priority Review." As far as I am aware no ASX-listed company has secured FDA Accelerated Approval to date. Mesoblast (ASX: MSB) is the closest, with its stem cell therapy Revascor for ischemic heart failure on the accelerated pathway. Dimerix (ASX: DXB) is also well-positioned, with its lead drug DMX-200 in a Phase 3 trial. The FDA has agreed that proteinuria reduction is an acceptable surrogate endpoint for potential Accelerated Approval and interim trial data expected in 2025 could support an early submission if results are strong. Neuren (ASX: NEU) received Fast Track Designation and later full standard approval for DAYBUE™ in Rett syndrome & Botanix (ASX: BOT) achieved standard FDA approval for Sofdra™ in hyperhidrosis. Neither Neuren nor Botanix went through the Accelerated Approval pathway #ASX #Biotech #FDA #AcceleratedApproval $BOT $BOT.AX $NEU $NEU.AX $DXB $DXB.AX Amplia Fast Track Designation ✅ Amplia Accelerated Approval 🔄🤞 Last week Amplia confirmed two pathological complete responses in their Accent Trial and have certainly strengthened their case for FDA Accelerated Approval.
1
4
1,413
$ATX $ATX.AX Broker Data (9 June - 22 June 2026) Retail selling. Bell Potter buying.
3
521
$CYP Another victim Phase 2 Graft vs Host Disease ☠️❌ Phase 3 Osteoarthritis Trial ☠️ ❌
3
500
$OPT $31.2m cash 1.368 billion shares on issue = approx $0.023 per share cash backing. Stock reinstated 3 June 2026 - got nuked 97% and has traded $0.012 - $0.016 range ever since. Regal were always going to sell as they lost over $200m on Opthea and wanted out at any price. Smart move by the Directors to relist in June and have an avalanche of selling for tax losses. Director Options have an exercise price at a 20% premium to the VWAP of the first 10 trading days post reinstatement and that window closes today 17 June 2026. Their option exercise price will probably be approx. $0.0175. $19m market cap ($0.014 per share) vs $31m cash. The market is valuing the whole thing approx 40% below cash. DYOR & Not advice.
1
2
307
$GOOG Google/Alphabet recently announced a $40 Billion ATM Facility as part of their proposed equity capital raising. In USA At-The-Market (ATM) offerings are used by leading companies to raise equity capital due to their highly cost efficient nature. The Australian equity market continues to lag the US.
130
Cynata Therapeutics $CYP Request for Voluntary Extension for Phase 3 & Phase 2 Trial results.
2
1
3
1,035
Cynata Therapeutics $CYP Request for Voluntary Extension for Phase 3 & Phase 2 Trial results.
1
1
795